Combination drug, application and kit for treating oral squamous cell carcinoma
By combining low-dose artemisinin with azole drugs, the problems of large chemotherapy toxicity and high single dose in oral squamous cell carcinoma treatment are solved, effectively inhibiting oral squamous cell cells and controlling the growth of ectopic tumors is achieved, and the patient can provide New treatment ideas.
Patent Information
- Application Number
- CN202211600272.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-12-13
AI Technical Summary
The existing oral squamous cell carcinoma treatment drugs are not effective, the chemotherapy is highly toxic, the single dose of artemisinin and azoles is high, the side effects are strong, and the combination mechanism has not yet been clarified.
Using low-dose artemisinin combined with azole antibacterial drugs, including dihydroartemisinin and miconazole, provides a low toxicity and low drug resistance by inhibiting oral squamous cell cell activity and ectopic tumor growth. sexual treatment options.
It effectively reduces the dosage of a single drug, reduces the toxicity of the drug, effectively inhibits the activity of oral squamous cell carcinoma cells, avoids the organ toxicity of chemotherapy drugs, and provides a new combination of new drugs for the treatment of oral squamous cell carcinoma.
Smart Images

Figure CN115845069B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biology and new medical technology, and in particular relates to a combination drug, application and kit for treating oral squamous cell carcinoma. Background Art
[0002] Oral squamous cell carcinoma is the most common head and neck tumor. In 2020, there were more than 370,000 new cases and more than 170,000 deaths worldwide. Oral squamous cell carcinoma patients' physiological functions such as language, swallowing and hearing will be seriously affected, greatly reducing their quality of life. However, early diagnosis of oral squamous cell carcinoma is insufficient and prone to recurrence, and the 5-year survival rate of patients is only about 50%. Surgery combined with radiotherapy and chemotherapy is the traditional treatment method for oral squamous cell carcinoma, but radiotherapy has many complications, and chemotherapy often causes drug resistance and organ toxicity. Therefore, new drugs with low toxicity and low drug resistance are urgently needed for the treatment of oral squamous cell carcinoma.
[0003] Artemisinin, known as "the gift of traditional Chinese medicine to the world", is extracted from Artemisia annua and is a class of sesquiterpenoid lactones. In 2015, Tu Youyou won the Nobel Prize in Physiology or Medicine for her research on the antimalarial effects of artemisinin. Since the 1970s, Tu Youyou's team has developed a series of artemisinin derivatives, including dihydroartemisinin, artemether and artesunate. The peroxy bridge group is the antimalarial functional group of artemisinin and its derivatives, which targets the membrane structure of malarial parasites and produces a large amount of reactive oxygen after breaking. In addition, artemisinin also has antibacterial and anti-tumor activities. In terms of anti-tumor, existing technologies have found that artemisinin and its derivatives can upregulate the expression of genes related to iron metabolism in lung cancer cells, and tumor cells show iron overload. Dihydroartemisinin can increase the intracellular iron content, thereby increasing the sensitivity of lung cancer, breast cancer and colon cancer cells to iron death inducers. In terms of anti-oral squamous cell carcinoma, dihydroartemisinin and artemether can kill tumor cells by inducing cell apoptosis, but the experimental results are higher than the clinical antimalarial safe dosage. Since artemisinin has the disadvantage of poor solubility, it is necessary to use a combination of drugs to achieve a low-dose, synergistic effect.
[0004] Azoles are broad-spectrum antifungal drugs that inhibit lanosterol 14-α-sterol demethylase, thereby blocking the synthesis of ergosterol in fungal cell membranes. Azoles can be divided into imidazoles and triazoles. Imidazoles include miconazole, econazole and ketoconazole, and triazoles include fluconazole and itraconazole. However, due to the coordination of the drug's N atom with the iron atom of the host cytochrome P450, azoles generally have significant liver and kidney toxicity. In addition to antibacterial effects, itraconazole can induce ferroptosis by increasing the accumulation of peroxides in nasopharyngeal carcinoma cells and consuming glutathione. Miconazole can activate Nrf2, a key factor in ferroptosis, to regulate the accumulation of reactive oxygen species in bladder cancer cells. However, apart from itraconazole, there have been no studies on other azoles against oral squamous cell carcinoma.
[0005] Through the above analysis, the problems and defects of the existing technology are: the existing oral squamous cell carcinoma treatment drugs are not effective, and oral squamous cell carcinoma chemotherapy is highly toxic, and artemisinin and azole drugs are used in high dosages and have strong side effects for oral squamous cell carcinoma.
[0006] The difficulty in solving the above problems and defects is that there has been no research on the combined use of artemisinin and azole drugs against oral squamous cell carcinoma, and the mechanism of their combination is still unclear.
[0007] The significance of solving the above problems and defects is that artemisinin and azole drugs are both first-line clinical drugs. Their combination is easier to clinically transform than the development of new drugs, and avoids the toxicity and induced drug resistance of chemotherapy drugs, providing new ideas for the treatment of oral squamous cell carcinoma. Summary of the invention
[0008] In order to overcome the problems existing in the related art, the disclosed embodiment of the present invention provides a combination drug for treating oral squamous cell carcinoma. The technical solution is as follows:
[0009] A combination drug for treating oral squamous cell carcinoma, comprising an effective amount of artemisinin and an azole antibacterial drug.
[0010] Furthermore, the artemisinin is artemisinin, artemether, artesunate and dihydroartemisinin or other structural analogs.
[0011] Furthermore, the azole antibacterial drug is ketoconazole, fluconazole, itraconazole, econazole and miconazole or other structural analogs.
[0012] Furthermore, the effective amount of the representative drug dihydroartemisinin is 5 μg / mL.
[0013] Furthermore, the effective amount of the representative azole antibacterial drug miconazole is 1 μg / mL.
[0014] Another object of the present invention is to provide a use of the combined drug for treating oral squamous cell carcinoma in the preparation of a drug for inhibiting the activity of oral squamous cell carcinoma cells.
[0015] Another object of the present invention is to provide a use of the combined drug for treating oral squamous cell carcinoma in the preparation of a drug for killing oral squamous cell carcinoma cells.
[0016] Another object of the present invention is to provide a use of the combined drug for treating oral squamous cell carcinoma in the preparation of a drug for inhibiting the growth of oral squamous cell carcinoma ectopic tumors.
[0017] Another object of the present invention is to provide a use of the combined drug for treating oral squamous cell carcinoma in the preparation of a drug for inhibiting tumor growth caused by oral squamous cell carcinoma cells.
[0018] Another object of the present invention is to provide a combination drug preparation kit for treating oral squamous cell carcinoma, comprising the combination drug for treating oral squamous cell carcinoma, characterized in that the combination drug preparation kit for treating oral squamous cell carcinoma comprises an effective amount of artemisinin and azole antibiotics.
[0019] Combining all the above technical solutions, the advantages and positive effects of the present invention are as follows:
[0020] The present invention reduces the dosage of a single drug and the toxicity of the drug by combining artemisinin and azole antibacterial drugs, and can effectively inhibit the activity of oral squamous cell carcinoma cells. The present invention avoids the organ toxicity of traditional chemotherapy drugs for treating oral squamous cell carcinoma. The combined drugs are all first-line clinical drugs. The low amount of artemisinin and azoles combined effectively inhibit the activity of oral squamous cell carcinoma cells. The present invention provides a new drug combination of artemisinin combined with azole antibacterial drugs for oral squamous cell carcinoma, which solves the problems of high toxicity of existing oral squamous cell carcinoma chemotherapy, high dosage of artemisinin and azole drugs for oral squamous cell carcinoma, and strong side effects.
[0021] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present disclosure. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present disclosure and, together with the description, serve to explain the principles of the present disclosure.
[0023] Figure 1 is a graph of Cal-27 cell viability after artemisinin combination treatment provided in an embodiment of the present invention; wherein, Figure 1 (a) is a graph of cell viability after artemisinin is combined with miconazole; Figure 1 (b) is a graph of cell viability after artemether is combined with miconazole; Figure 1 (c) is a graph of cell viability after artemisinin succinate is combined with miconazole; Figure 1 (d) is a graph of cell viability after dihydroartemisinin is combined with miconazole; Figure 1 (e) is a graph of cell viability after dihydroartemisinin is combined with ketoconazole; Figure 1 (f) is a graph of cell viability after dihydroartemisinin is combined with fluconazole; Figure 1 (g) is a graph of cell viability after dihydroartemisinin is combined with itraconazole; Figure 1 (h) is a graph of cell viability after dihydroartemisinin is combined with econazole.
[0024] Figure 2 This is a graph showing the effects of the combination of dihydroartemisinin and miconazole on the viability of oral epithelial keratinocytes HOK, oral mucosal precancerous lesion cells DOK, and tongue squamous cell carcinoma cells Cal-27, HSC-3, SAS, and SCC-25 provided by an embodiment of the present invention.
[0025] Figure 3 This is a graph showing the colony-forming ability of Cal-27 cells after the use of dihydroartemisinin and miconazole alone and in combination, as provided in an embodiment of the present invention.
[0026] Figure 4 It is a schematic diagram of the percentage of dead Cal-27 cells detected by flow cytometry after single use and combined use of DHA and MICO (the scatter plot is a representative picture of the flow cytometry results) provided by an embodiment of the present invention.
[0027] Figure 5 It is a curve diagram of the change of the volume of oral squamous cell carcinoma ectopic tumor over time provided by an embodiment of the present invention.
[0028] Figure 6 This is a tumor volume diagram after the drug treatment provided by the embodiment of the present invention is completed.
[0029] Figure 7 This is a tumor mass diagram after the drug treatment provided by the embodiment of the present invention is completed. DETAILED DESCRIPTION
[0030] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below in conjunction with the accompanying drawings. In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without violating the connotation of the present invention, so the present invention is not limited by the specific implementation disclosed below.
[0031] The embodiment of the present invention provides a combination drug for treating oral squamous cell carcinoma, wherein the combination drug for treating oral squamous cell carcinoma comprises an effective amount of artemisinin and an azole antibiotic.
[0032] The artemisinin provided in the embodiments of the present invention is various structural analogs such as artemisinin, artemether, artesunate and dihydroartemisinin.
[0033] The azole antibacterial drugs provided in the embodiments of the present invention are various structural analogs such as ketoconazole, fluconazole, itraconazole, econazole and miconazole.
[0034] The effective amount of the representative dihydroartemisinin provided in the embodiments of the present invention is 5 μg / mL.
[0035] The effective amount of miconazole, a representative azole antibacterial drug provided in the embodiment of the present invention, is 1 μg / mL.
[0036] The technical solution of the present invention is further described below in conjunction with specific embodiments.
[0037] Embodiment 1:
[0038] 1. Artemisinin combined with azole drugs inhibits the activity of oral squamous cell carcinoma cells
[0039] 1. Main Reagents
[0040] Fetal bovine serum (FBS) (Gibco, USA)
[0041] Penicillin–streptomycin antibiotic mixture (PS) (Hyclone, Logan, UT, USA)
[0042] DMEM high glucose medium (Dulbecco's modified Eagle Medium, Hyclone, Logan, UT, USA)
[0043] Pancreatic enzyme (Trypsin, Hyclone, Logan, UT, USA)
[0044] Dimethyl sulfoxide (DMSO) (MP Biomedicals, USA)
[0045] Ketoconazole (KET) (CAS: 65277-42-1, MCE, USA)
[0046] Artemisinin (ART) (CAS: 63968-64-9, J&K Technology, China)
[0047] Artesunate (ARS) (CAS: 88495-63-0, J&K Technology, China)
[0048] Artemether (ARM) (CAS: 71963-77-4, J&K Technology, China)
[0049] Dihydroartemisinin (DHA) (CAS: 71939-50-9, J&K Technology, China)
[0050] Fluconazole (FLUCZ) (CAS: 86386-73-4, J&K Technology, China)
[0051] Itraconazole (ITRAC) (CAS: 84625-61-6, J&K Technology, China)
[0052] Econazole (ECO) (CAS: 27220-47-9, Yuanye Biotechnology, China)
[0053] Miconazole nitrate (MICO) (CAS: 22832-87-7, MCE, USA)
[0054] CCK8 Appreciation Detection Kit (APExBIO, USA)
[0055] Giemsa dye solution (Solarbio, China)
[0056] Annexin-FITC / PI apoptosis detection kit (dojindo, Japan)
[0057] 2. Main instruments
[0058] CO2 Cell Culture Incubator (Shanghai, China)
[0059] Clean bench (Thermo Forma Scientific, USA)
[0060] Electronic cell counter (Bio-Rad, TC20™, USA)
[0061] Inverted microscope (Leica, Germany)
[0062] Small normal temperature centrifuge (Eppendorf, Germany)
[0063] Multifunctional enzyme-linked immunosorbent assay (Molecular Devices, USA)
[0064] Flow cytometer (Millipore Guava, France)
[0065] Stereo microscope (Leica, Germany)
[0066] 3. Experimental Methods
[0067] 3.1 CCK-8 assay to detect cell viability
[0068] 100 μL of cell suspension was inoculated into each well of a 96-well plate, with a cell density of 5000 cells / well. Three parallel wells were set up for each experimental group, and each experiment was repeated three times independently. The plate was incubated at 37 °C and 5% CO 2Pre-culture in the incubator for 24 h. After the cells adhered to the wall, the original complete medium was removed, and the cells were washed once with sterile PBS. 100 μL of experimental medium (DMEM high-glucose medium containing 2% FBS and no PS) was added to each well, and 1 μL of the drug solution to be tested was added to the well (the drug solution was prepared as a stock solution using DMSO as a solvent, and then diluted 10 times with the experimental medium to ensure that the DMSO concentration in the final system of each well was ≤0.1%). The well plate was incubated at 37°C and 5% CO 2 Continue to culture in the incubator. Before the test, aspirate the medium containing drugs, wash once with PBS, and add 90 μL DMEM high glucose medium and 10 μL CCK-8 solution to each well of the plate. Incubate the culture plate in the incubator in the dark for 1-4 h, and measure the optical density (OD) at 450 nm with a multifunctional enzyme-linked immunosorbent assay. The formula for calculating cell viability is: cell viability (%) = (OD experimental group-OD culture medium) / (OD control group-OD culture medium) × 100%.
[0069] 3.2 Cell colony assay
[0070] Cells were seeded in 6-well plates at a cell density of 2 × 10 5 At 37°C, 5% CO 2 Pre-culture in the incubator for 24 hours. After the cells adhere to the wall, remove the original complete medium, wash once with PBS, add 2 mL of experimental medium to each well, and add 20 μL of the drug solution to be tested (prepared as in 1.2.2) to the well. Continue to incubate the well plate at 37 °C, 5% CO 2 Cultured in an incubator for 24 h, then digested with trypsin and collected for counting. Cells were inoculated in 60 mm cell culture dishes at a density of 600 cells / dish, with 3 parallel dishes set up for each group. Further cultured in a 37 °C, 5% CO2 incubator for 2 weeks, with complete culture medium replaced every 2 days. After the culture was completed, the culture medium was discarded, washed twice with PBS solution, and air dried. Methanol was fixed for 15 min, and the methanol was discarded and air dried. Stained with Giemsa stain for 10 min, the stain was slowly washed away with running water until there were no dye impurities, and air dried until there were no obvious water droplets. The number of cell colonies formed was counted (colony standard: >50 cells or staining diameter >500 μm is a cell colony).
[0071] 3.3 Annexin-FITC / PI fluorescence labeling to detect cell death
[0072] Seed cells in a 60 mm cell culture dish at a cell density of 2-3 × 10 5 pcs / dish, at 37°C, 5% CO 2Pre-culture in the incubator for 24 h. After the cells adhere to the wall, remove the original complete medium, wash once with PBS, add 3 mL of experimental medium to each well, and add 30 μL of the drug solution to be tested (prepared as in 1.2.2) to the well. Continue to incubate the well plate at 37 °C and 5% CO 2 Culture in the incubator for 24 h. Transfer the supernatant from the culture dish to a 15 mL sterile centrifuge tube for storage, wash the cells twice with PBS, and collect the washing solution for storage. Digest the cells with 500 μL of EDTA-free trypsin, incubate at 37 °C until the cells are in a flowing sand state, collect the cell suspension with a culture medium 3 times the volume of trypsin and transfer it to a centrifuge tube. Centrifuge at room temperature at 1000 rpm for 3 min, and discard the supernatant. Add an appropriate volume of PBS to wash and resuspend, centrifuge at room temperature at 1000 rpm for 3 min, discard the supernatant, and repeat this operation once. Dilute 10×AnnexinV Binding Solution with ultrapure water to prepare 1×Annexin V Binding Solution. Add 1×AnnexinV Binding Solution to the cell centrifugal precipitate to prepare a cell suspension with a final concentration of 1×106 cells / ml. Take 100 μL of cell suspension and add it to a sterile Ep tube. Add 5 μL Annexin V, FITC conjugate to the cell suspension, then add 5 μL PI Solution, incubate at room temperature in the dark for 15 min, and add 400 μL 1×Annexin V BindingSolution. Before the experiment, set up 3 groups of controls: unstained cells, Annexin V, FITC stained cells (without PI) and PI stained cells (without Annexin V, FITC). Analyze cell death by flow cytometry within 1 hour, excitation wavelength Ex = 488 nm; emission wavelength Em = 530 nm, AnnexinV-FITC green fluorescence is detected through FITC channel (FL1); PI red fluorescence is detected through PI channel (FL2 or FL3). This experiment was repeated 3 times independently
[0073] 2. Artemisinin combined with azole drugs inhibits the growth of oral squamous cell carcinoma ectopic tumors in mice
[0074] 1. Main Reagents
[0075] Fetal bovine serum (FBS) (Gibco, USA)
[0076] Penicillin–streptomycin antibiotic mixture (PS) (Hyclone, Logan, UT, USA)
[0077] DMEM high glucose medium (Dulbecco's modified Eagle Medium, Hyclone, Logan, UT, USA)
[0078] Pancreatic enzyme (Trypsin, Hyclone, Logan, UT, USA)
[0079] Dimethyl sulfoxide (DMSO) (MP Biomedicals, USA)
[0080] Dihydroartemisinin (DHA) (CAS: 71939-50-9, J&K Technology, China)
[0081] Miconazole nitrate (MICO) (CAS: 22832-87-7, MCE, USA)
[0082] 4% paraformaldehyde (Solarbio, China)
[0083] 2. Main instruments
[0084] CO2 Cell Culture Incubator (Shanghai, China)
[0085] Clean bench (Thermo Forma Scientific, USA)
[0086] Electronic cell counter (Bio-Rad, TC20™, USA)
[0087] Inverted microscope (Leica, Germany)
[0088] Small normal temperature centrifuge (Eppendorf, Germany)
[0089] 3. Experimental Methods
[0090] 3.1 Immunodeficient mice
[0091] Bal / bc immunodeficient mice were purchased from Jiangsu Jicui Pharmaceutical Co., Ltd., female, 4-6 weeks old, and weighing (20+2 g). The mice were raised in the Experimental Animal Center of West China Second Hospital, Sichuan University, in a specific pathogen free (SPF) environment with an individually ventilated cage (IVC) barrier system. This invention has been approved by the Ethics Committee of West China Hospital of Stomatology, Sichuan University (Approval No.: WCHSIRB-D-2020-413).
[0092] 3.2 Effects of drug combination on the growth of oral squamous cell carcinoma in vivo
[0093] Construction of oral squamous cell carcinoma subcutaneous heterotopic transplant tumor model: Cal-27 cells were cultured and collected to make suspension, with a cell density of 1×10 7 200 μL of cell suspension was injected subcutaneously into the back of the mouse. One week after tumor formation, the experimental treatment began.
[0094] The experiment was divided into 5 groups: ① blank group; ② control group; ③ dihydroartemisinin; ④ miconazole; ⑤ dihydroartemisinin + miconazole. There were 5 mice in each group.
[0095] Experimental treatment: Intraperitoneal injection of drug solution, dihydroartemisinin injection dose was 9.1 mg / kg, miconazole injection dose was 1.82 mg / kg, and the control group was intraperitoneally injected with sterile PBS. The drug was given every other day and the tumor size was measured and recorded. The treatment time was 21 days.
[0096] The chessboard method combined four artemisinins: artemisinin, artemether, artesunate, and dihydroartemisinin, and five azole drugs: ketoconazole, fluconazole, itraconazole, econazole, and miconazole. The CCK-8 method was used to explore the effect of dihydroartemisinin on the proliferation of Cal-27 cells over 24 hours. The two had a synergistic effect. Dihydroartemisinin and econazole or miconazole combined with dihydroartemisinin had a good inhibitory effect on activity (Figure 1 (a)-Figure 1 (h)). Due to the organ toxicity of azole drugs, they are mostly applied topically in antifungal applications, but miconazole can be used for blood injection in small quantities. For subsequent clinical transformation, this experiment selected dihydroartemisinin and miconazole as the best drug combination.
[0097] After determining the best drug combination, the activity of the drug combination was further verified using different cell lines, including oral epithelial keratinocyte cell line HOK, oral mucosal precancerous cell line DOK, tongue squamous cell carcinoma cell lines Cal-27, HSC-3, SAS, and SCC-25. The results showed that dihydroartemisinin 5μg / mL and miconazole 1μg / mL concentrations had a significant inhibitory effect on all cells ( Figure 2 ).
[0098] After screening the optimal drug combination of dihydroartemisinin + miconazole, this experiment verified its ability to kill Cal-27 cells. The results of the cell colony experiment showed that dihydroartemisinin and miconazole alone did not affect the cell clustering ability of Cal-27, but the combined use significantly reduced the formation of cell colonies, proving that the combined drug treatment inhibited the viability of Cal-27 cells ( Figure 3 Flow cytometry showed that dihydroartemisinin + miconazole significantly increased the number of cell death ( Figure 4 ). In summary, dihydroartemisinin + miconazole promoted the death of Cal-27 cells.
[0099] In order to verify the effect of dihydroartemisinin + miconazole on oral squamous cell carcinoma cells, this experiment established a tongue squamous cell carcinoma ectopic tumor model in Bal / bc immunodeficient mice, and injected dihydroartemisinin and miconazole alone or in combination into the abdominal cavity. From the 4th day, the tumor growth of mice in the combination group was stagnant, while the tumor volume of the control group and the drug single group continued to increase ( Figure 5 The experiment was ended after 21 days of drug administration. The tumor tissues were obtained by dissecting the mice. The tumor volume and mass of the dihydroartemisinin + miconazole group were significantly smaller than those of the control group, the dihydroartemisinin alone group, and the miconazole alone group ( Figure 6-Figure 7 ). The above results show that the combination of dihydroartemisinin + miconazole significantly inhibited the growth of oral squamous cell carcinoma ectopic tumors in vivo.
[0100] Figure 1 to Figure 7 In the table, *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; ns: no statistical difference.
[0101] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principles of the present invention should be covered within the protection scope of the present invention.
Claims
1. Application of dihydroartemisinin and miconazole in combination for the preparation of drugs for inhibiting the activity of oral squamous cell carcinoma cells.
2. The application of dihydroartemisinin and miconazole in the preparation of drugs for inhibiting the growth of oral squamous cell carcinoma ectopic tumors.
3. The use of dihydroartemisinin and miconazole in combination for the preparation of drugs for inhibiting tumor growth caused by oral squamous cell carcinoma cells.
4. The use according to any one of claims 1 to 3, characterized in that: The effective amount of dihydroartemisinin is 5 μg / mL, which is used to reduce the dosage of a single drug.
5. The use according to any one of claims 1 to 3, characterized in that: The effective amount of miconazole is 1 μg / mL, which is used to reduce the toxicity of a single drug.
